Seeking Alpha

Marty Chilberg's  Instablog

Marty Chilberg
Send Message
I'm a retired CPA who spent the majority of his working career in technology companies. My work included management stints at Atari Inc, Daisy Systems Corp, Symantec Corp and Visio Corp. My last position at Visio (VSIO) was as CFO and VP Finance and Operations.
View Marty Chilberg's Instablogs on:
  • Market Research Report On NIPT

    Market research report should be published next week. Table of Contents preview:

    Market Analysis of Non-Invasive Prenatal Screening

    Summary

    Sizing the Market

    • Overview
    • Birth rate
    • Risk segments
    • Payer profile
    • Market size conclusions

    Focus International Markets

    • Brazil
    • Mexico
    • EU 5
    • China
    • India
    • Japan

    Americas Market

    • North
    • Central
    • Caribbean
    • South

    European Market

    • Northern
    • Western
    • Eastern
    • Southern

    Asian Market

    • Western
    • South Central
    • Southeast
    • East

    Rest of World Market

    • Africa
    • Oceania

    Investing the Space

    • Ariosa Diagnostics, Inc. (AROS)
    • Illumina, Inc. (ILMN)
    • Natera, Inc. (private)
    • Sequenom, Inc. (SQNM)

    NIPT Market Summary

    Disclosure: I am long SQNM.

    Apr 18 1:21 PM | Link | Comment!
  • Ariosa Amended S-1: Roadshow Next

    Ariosa (AROS) amended their Form S-1 to include Q1-2014 results. A few highlights included in new filing:

    Q1-14 revenues $19.5 vs $9.6 PY

    • ASP $377 vs $380
    • International $6.9m vs $0.6m
    • Domestic $12.6m vs 9.0m
    • Tests 51,700 vs 25,200
    • LabCorp $12.1m vs $9.0m

    Q1-14 net income of $1.1m

    Cash increased sequentially to $16.8m from $14M

    Company included disclosure that they expected to generate losses after this quarter. Likely due to the incremental spend in SG&A and some disruption from amended LabCorp agreement.

    International revenues of approximately $7m compares with Sequenom reported results in Q4-13 of $3.7m. Clearly appears that internationally Ariosa has a substantial advantage currently.

    Disclosure: I am long SQNM.

    Apr 17 1:04 PM | Link | Comment!
  • Proposed Amendments To EU Regulation On Medical Devices Are Counter To Patients' Interests And Unworkable, Says ESHG

    Recent amendments to the proposed Regulation on In Vitro Diagnostic Medical Devices (IVDs) currently before the European Parliament will restrict the rights of patients and doctors to carry out essential genetic testing, says the European Society of Human Genetics (OTC:ESHG) today (Monday 7 April 2014). Furthermore, an independent legal opinion now shows that the European Union (EU) has no competence to enact the Regulation as amended by the Parliament.

    The new Regulation was proposed by the European Commission in order to bring the regulation of diagnostic kits or IVDs up to date. The ESHG has welcomed the Commission's proposal as it will 'improve the quality, safety availability and oversight of IVDs marketed and used in the European Union.'

    However amendments, proposed by German MEP Peter Liese, call for mandatory detailed genetic counselling to accompany every genetic test and hold the person carrying out a genetic test responsible for the rights, safety and well-being of the test subjects. The amendments say that genetic counselling should be appropriate and comprehensible and that it should include medical, ethical, social, psychological and legal aspects. "These are praiseworthy objectives with which no-one would disagree, but they are well beyond the scope of a regulation on the safety of IVDs," said Dr David Barton, from the National Centre for Medical Genetics, Dublin, Ireland, speaking on behalf of the ESHG.

    "Medical practice, including genetic medicine, is organised and delivered in many different ways in different Member States. This proposed article encroaches on this diversity and seeks to dictate in detail the arrangements for every clinic where a genetic test may be ordered. It insists on the direct involvement of a medical doctor in every patient interaction, where, in reality, it is common practice for genetic tests to be ordered by other healthcare professionals such as genetic counsellors under the supervision of a medical doctor.

    "Marvellous advances in genetic science are bringing genetic testing into every area of medicine. The proposals set out here seek to impose a single restrictive template on all genetic tests; this is unworkable and can only impede the progress of medical practice in the EU," he said.

    The new legal opinion, from the respected life science law firms Lawford Davies Denoon and Axon Lawyers, says that because the proposed amendments are outside the competence of the EU, if a Regulation were to be enacted incorporating the new articles, it could be challenged on the grounds of 'infringement of the principle of subsidiarity by a legislative act.'

    "We hope that the European Council will now consider these proposals in the light of the competence of the EU", says Dr Barton "We are gravely concerned that these proposals, as they stand, restrict legitimate, ethically-acceptable genetic testing activities such as the screening of new-born babies. They infringe on accepted and acceptable clinical practice when they should simply be regulating IVDs, effectively hijacking a sound and important Regulation to interfere with carefully regulated clinical practice, and infringing on patients' autonomy."

    www.eshg.org/566.0.html

    Apr 14 12:00 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.